Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Erythropoietin (EPO), originally discovered as hematopoietic growth factor, has direct effects on cells of the nervous system that make it a highly attractive candidate drug for neuroprotection/neuroregeneration. Hardly any other compound has led to so much preclinical work in the field of translational neuroscience than EPO. Almost all of the >180 preclinical studies performed by many independent research groups from all over the world in the last 12 years have yielded positive results on EPO as a neuroprotective drug. The fact that EPO was approved for the treatment of anemia >20 years ago and found to be well tolerated and safe, facilitated the first steps of translation from preclinical findings to the clinic. On the other hand, the same fact, naturally associated with loss of patent protection, hindered to develop EPO as a highly promising therapeutic strategy for application in human brain disease. Therefore, only few clinical neuroprotection studies have been concluded, all with essentially positive and stimulating results, but no further development towards the clinic has occurred thus far. This article reviews the preclinical and clinical work on EPO for the indications neuroprotection/neuroregeneration and cognition, and hopefully will stimulate new endeavours promoting development of EPO for the treatment of human brain diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
Semenza, G. L. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.88.4.1474 · Cited by 1,822
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Self-citationEmerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression
Fandrey, J. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00577.2003 · Cited by 243
Erythropoietin: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE
Yuan, R., Maeda, Y., Li, W., Lu, W., Cook, S., & Dowling, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001924 · Cited by 94
Zechariah, A., ElAli, A., & Hermann, D. M. (2010) · Stroke · doi:10.1161/strokeaha.109.574418 · Cited by 84
Li, L., Jiang, Q., Ding, G., Zhang, L., Zhang, Z. G., Li, Q., Panda, S., Kapke, A., Lu, M., Ewing, J. R., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.527713 · Cited by 67
Miskowiak, K. W., Favaron, E., Hafizi, S., Inkster, B., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1842-7 · Cited by 40
Cited by
Peripheral nerve injury and myelination: Potential therapeutic strategies
Modrak, M., Talukder, M. A. H., Gurgenashvili, K., Noble, M., & Elfar, J. C. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24538 · Cited by 266
Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
Carvalho, A., Miskowiak, K., Hyphantis, T., Kohler, C., Alves, G., Bortolato, B., G. Sales, P., Machado-Vieira, R., Berk, M., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130203627 · Cited by 107
Miskowiak, K. W., Vinberg, M., Christensen, E. M., Bukh, J. D., Harmer, C. J., Ehrenreich, H., & Kessing, L. V. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.335 · Cited by 104
“Erythropoietin (EPO) is well known for its effects on red blood cells but is also produced in the brain (Marti et al, 1996) where it has a key role in neuroprotection and development (Siren et al, 2009), and in cognitive function (Kästner et al, 2012; Sargin et al, 2010).”
BackgroundSelf-citationEffects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders
Miskowiak, K. W., Vinberg, M., Macoveanu, J., Ehrenreich, H., Køster, N., Inkster, B., Paulson, O. B., Kessing, L. V., Skimminge, A., & Siebner, H. R. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.12.013 · Cited by 99
Self-citationNeuroplasticity and the next wave of antidepressant strategies
Hayley, S., & Litteljohn, D. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00218 · Cited by 92
“Specifically, two small-scale trials have been published to-date examining the efficacy of the glutamatergic modulator, riluzole (which is used to prolong survival in Amytrophic Lateral Sclerosis), in delaying relapse among ketamine-remitted patients with treatmentresistant depression (Mathew et…”
BackgroundInfluential
Metadata
- Authors
- Sargin, D., Friedrichs, H., El-Kordi, A., & Ehrenreich, H.
- Venue
- Best Practice & Research Clinical Anaesthesiology
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 24
- Issue
- 4
- Pages
- 573-594
- ISSN
- 1521-6896 (ISSN-L)
- OpenAlex
- W2103255946
- Cited by
- 152
- References
- 10
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. https://app.cochat.ai/papers/10.1016/j.bpa.2010.10.005
- The paper
- Sargin, D., Friedrichs, H., El-Kordi, A., & Ehrenreich, H. (2010). Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. Best Practice & Research Clinical Anaesthesiology. https://doi.org/10.1016/j.bpa.2010.10.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.